Satsuma Pharmaceuticals Announces First Subject Randomized in SUMMIT ™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine
SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 28, 2021 Category: Pharmaceuticals Source Type: clinical trials

Johnson & Johnson Statement on U.S. FDA Approval of Shelf Life Extension for Company ’s COVID-19 Vaccine
NEW BRUNSWICK, N.J., July 28, 2021 -- We are pleased to confirm the U.S. Food& Drug Administration (FDA) has extended the shelf life for the Johnson& Johnson single-shot COVID-19 vaccine to six months. The decision is based on data... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 28, 2021 Category: Pharmaceuticals Source Type: clinical trials

New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition
NORTH CHICAGO, Ill., July 25, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced new data, including the full results from the Phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 25, 2021 Category: Pharmaceuticals Source Type: clinical trials

Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
WILMINGTON, Del.--(BUSINESS WIRE) July 23, 2021 -- Incyte Corporation (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 23, 2021 Category: Pharmaceuticals Source Type: clinical trials

Vaxzevria is Highly Effective After One Dose Against Severe Disease or Hospitalisation Caused by Beta and Delta Variants of Concern
23 July 2021 Real-world data from Canada showed 82% and 87% effectiveness after one dose against hospitalisation or death caused by Beta/Gamma and Delta variants respectively Results from the Canadian Immunization Research Network (CIRN)... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 23, 2021 Category: Pharmaceuticals Source Type: clinical trials

Anthos Therapeutics' Novel Factor XI Inhibitor Abelacimab Significantly Outperforms Standard of Care Enoxaparin in Prospective Phase 2 Efficacy Research Published in NEJM
CAMBRIDGE, Mass., July 19, 2021 /PRNewswire/ -- Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced final results from the Phase 2 ANT-005... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 19, 2021 Category: Pharmaceuticals Source Type: clinical trials

Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
BOSTON--(BUSINESS WIRE)--Jul. 19, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has begun a Phase 2 proof-of-concept (POC) study in acute pain following bunionectomy surgery with the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 19, 2021 Category: Pharmaceuticals Source Type: clinical trials

New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul. 17, 2021-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced new results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir, the company’s investigational, long-acting HIV-1... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 17, 2021 Category: Pharmaceuticals Source Type: clinical trials

GSK Announces Positive Headline Results from Five Phase 3 Studies of Daprodustat for Patients with Anemia due to Chronic Kidney Disease
Issued: London UK– GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive headline results from five studies of the Phase 3 ASCEND programme, evaluating the efficacy and safety profile of daprodustat, an investigational oral... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 16, 2021 Category: Pharmaceuticals Source Type: clinical trials

Basis for BioVie ’s Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimer’s Disease Published in Neurodegenerative Disease Management
SANTA MONICA, Calif., July 16, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that an article... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 16, 2021 Category: Pharmaceuticals Source Type: clinical trials

Lilly and Banner Alzheimer's Institute Collaborate on Planned Phase 3 Prevention Trial of Donanemab
INDIANAPOLIS and PHOENIX, July 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Banner Alzheimer's Institute today announced a strategic research collaboration as part of the planned Phase 3,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 15, 2021 Category: Pharmaceuticals Source Type: clinical trials

Johnson & Johnson Single-Shot COVID-19 Vaccine Demonstrated a Durable Immune Response and Elicited Dual Mechanisms of Protection Against Delta and Other SARS-CoV-2 Variants of Concern in Data Published in New England Journal of Medicine
Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) over time NEW BRUNSWICK, N.J., July 14, 2021 – Interim... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 14, 2021 Category: Pharmaceuticals Source Type: clinical trials

Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
KENILWORTH, N.J.& MIAMI--(BUSINESS WIRE) July 12, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the presentation of previously announced Phase 2 interim results from... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 12, 2021 Category: Pharmaceuticals Source Type: clinical trials

Johnson & Johnson Statement on COVID-19 Vaccine Following Reports of Guillain-Barre ́ Syndrome
NEW BRUNSWICK, N.J., July 12, 2021 -- The safety and well-being of the people who use our products is our number one priority. Rare cases of the neurological disorder, Guillain-Barre ́ syndrome have been reported following vaccination with the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 12, 2021 Category: Pharmaceuticals Source Type: clinical trials

Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis
Orelabrutinib is a Phase 2 oral small molecule Bruton’s tyrosine kinase inhibitor with high selectivity and the ability to cross the blood-brain barrier InnoCare to receive a $125 million upfront payment and is eligible to receive potential... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 12, 2021 Category: Pharmaceuticals Source Type: clinical trials

Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study
INDIANAPOLIS, July 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced new Phase 2 data showing that gene expression changes induced by mirikizumab in patients with ulcerative colitis (UC) over a 12-week induction... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 9, 2021 Category: Pharmaceuticals Source Type: clinical trials

FDA Approves Updated Aduhelm Prescribing Information to Emphasize Population Studied in Clinical Trials
Aduhelm should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia CAMBRIDGE, Mass. and TOKYO, July 08, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd.... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 8, 2021 Category: Pharmaceuticals Source Type: clinical trials

Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 7, 2021-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participants have been dosed in the Phase 1/2... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 7, 2021 Category: Pharmaceuticals Source Type: clinical trials

Merck Provides Update on Keytruda (pembrolizumab) Indication in Third-Line Gastric Cancer in the US
KENILWORTH, N.J.--(BUSINESS WIRE) July 1, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company plans to voluntarily withdraw the U.S. accelerated approval indication for Keytruda for the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 1, 2021 Category: Pharmaceuticals Source Type: clinical trials

Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
NEW BRUNSWICK, N.J., July 1, 2021 – Johnson& Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 1, 2021 Category: Pharmaceuticals Source Type: clinical trials

Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine
GAITHERSBURG, Md., June 30, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication of results from the final... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 30, 2021 Category: Pharmaceuticals Source Type: clinical trials

Vaxzevria Induced Immunity for at Least One Year Following a Single Dose and Strong Immune Responses Following Either a Late Second Dose or a Third Dose
28 June 2021 -- A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a third boosting dose. The... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 28, 2021 Category: Pharmaceuticals Source Type: clinical trials

Nirsevimab MEDLEY Phase II/III Trial Demonstrated Favourable Safety and Tolerability Profile in Infants at High Risk of RSV
28 June 2021 -- The MEDLEY Phase II/III trial evaluated the safety and tolerability of nirsevimab compared to Synagis (palivizumab) when given to infants at high risk of respiratory syncytial virus (RSV) entering their first RSV... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 28, 2021 Category: Pharmaceuticals Source Type: clinical trials

First COVID-19 Variant Vaccine AZD2816 Phase II/III Trial Participants Vaccinated
27 June 2021 -- The first participants in a Phase II/III trial for the new COVID-19 variant vaccine AZD2816 were vaccinated today to assess its safety and immunogenicity in both previously vaccinated and unvaccinated adults. The trial will recruit... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 27, 2021 Category: Pharmaceuticals Source Type: clinical trials

Lilly's SURPASS-1 Results Published in The Lancet Show Tirzepatide's Superior A1C and Body Weight Reductions Versus Placebo in Adults with Type 2 Diabetes
INDIANAPOLIS, June 26, 2021 /PRNewswire/ -- Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes after 40 weeks of treatment in Eli Lilly and Company's (NYSE:... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 26, 2021 Category: Pharmaceuticals Source Type: clinical trials

Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
CAMBRIDGE, Mass. and TARRYTOWN, N.Y., June 26, 2021 /PRNewswire/ -- First-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humans Interim readout in ongoing Phase 1 trial finds... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 26, 2021 Category: Pharmaceuticals Source Type: clinical trials

Lilly's SURPASS-2 Results Published in The New England Journal of Medicine Show Tirzepatide Achieved Superior A1C and Body Weight Reductions Compared to Injectable Semaglutide in Adults with Type 2 diabetes
INDIANAPOLIS, June 25, 2021 /PRNewswire/ -- Tirzepatide led to superior A1C and body weight reductions from baseline compared to injectable semaglutide 1 mg in 40-week results from Eli Lilly and Company's (NYSE: LLY) SURPASS-2 clinical... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 25, 2021 Category: Pharmaceuticals Source Type: clinical trials

Veru Enrolls First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin (VERU-111) in Metastatic Castration Resistant and Androgen Receptor Targeting Agent Resistant Prostate Cancer
MIAMI, June 25, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that it has enrolled the first... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 25, 2021 Category: Pharmaceuticals Source Type: clinical trials

Treatment With Hepcludex (bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun. 24, 2021-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from the Phase 2b and Phase 3 clinical trials evaluating the first-in-class entry inhibitor... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 24, 2021 Category: Pharmaceuticals Source Type: clinical trials

Lilly's Donanemab receives U.S. FDA's Breakthrough Therapy Designation for Treatment of Alzheimer's disease
INDIANAPOLIS, June 24, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's (NYSE: LLY) investigational antibody therapy for Alzheimer's... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 24, 2021 Category: Pharmaceuticals Source Type: clinical trials

Genentech ’s Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and Children
South San Francisco, CA -- June 24, 2021 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 24, 2021 Category: Pharmaceuticals Source Type: clinical trials

Resolve Therapeutics Receives FDA Approval to Initiate Phase 2 Clinical Trial of RSLV-132 in Long Covid Patients
ST. PETERSBURG, Fla., June 23, 2021 /PRNewswire/ -- Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced that the US Food and Drug Administration has approved a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 23, 2021 Category: Pharmaceuticals Source Type: clinical trials

Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation for Lecanemab (BAN2401), an Anti-Amyloid Beta Protofibril Antibody for the Treatment of Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass, -- June 23, 2021 -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,“Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos,“Biogen”)... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 23, 2021 Category: Pharmaceuticals Source Type: clinical trials

Biogen and Eisai Update for the Alzheimer ’s Disease Community
CAMBRIDGE, Mass. and WOODCLIFF LAKE, N.J., June 23, 2021 – Biogen (Nasdaq: BIIB) and Eisai Inc., U.S. subsidiary of Eisai Co., Ltd. today issued the following statement: On June 7, 2021, Aduhelm™ (aducanumab-avwa)... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 23, 2021 Category: Pharmaceuticals Source Type: clinical trials

Seal Rock Therapeutics Announces Initiation of Phase 1 Clinical Trial of ASK1 Inhibitor SRT-015 for NASH
June 23, 2021, Seattle, WA – Seal Rock Therapeutics, Inc., a clinical stage biotechnology company developing a platform of first-in-class and best-in-class therapeutic kinase inhibitors for treatments of severe fibrotic and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 23, 2021 Category: Pharmaceuticals Source Type: clinical trials

Emalex Biosciences Announces Completion of Patient Enrollment in Phase 2b Clinical Trial Evaluating Ecopipam (EBS-101) for Pediatric Patients with Tourette Syndrome
CHICAGO, June 22, 2021 /PRNewswire/ -- Emalex Biosciences, Inc. ( " Emalex " ), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 22, 2021 Category: Pharmaceuticals Source Type: clinical trials

Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
LEXINGTON, Mass.--(BUSINESS WIRE) June 22, 2021 -- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the“Company” or“Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 22, 2021 Category: Pharmaceuticals Source Type: clinical trials

Xentria Announces the Initiation of a Clinical Trial for XTMAB-16 for the Treatment of Sarcoidosis
CHICAGO--(BUSINESS WIRE) June 22, 2021--Xentria Inc., a biopharmaceutical company focused on developing novel biologics to address unmet clinical needs, today announced that the U.S. Food and Drug Administration (“FDA”) has confirmed... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 22, 2021 Category: Pharmaceuticals Source Type: clinical trials

GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Programme for Sotrovimab
Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces hospitalisation and risk of death in adults with mild-to-moderate COVID-19 who are at high risk of progression to severe disease U.S. National Institutes of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 21, 2021 Category: Pharmaceuticals Source Type: clinical trials

Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis
IRVINE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 21, 2021 Category: Pharmaceuticals Source Type: clinical trials

Theravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19
DUBLIN and SOUTH SAN FRANCISCO, Calif., June 21, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ( " Theravance Biopharma " or the " Company " ) (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 21, 2021 Category: Pharmaceuticals Source Type: clinical trials

Biogen Announces First Patient Dosed with BIIB059 in Phase 3 Systemic Lupus Erythematosus Study
Global Phase 3 TOPAZ-1 study will evaluate the efficacy and safety of BIIB059, as compared to placebo, in active systemic lupus erythematosus (SLE), a debilitating autoimmune disease which has limited treatment... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 17, 2021 Category: Pharmaceuticals Source Type: clinical trials

REGEN-COV ™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2
TARRYTOWN, N.Y., June 16, 2021 /PRNewswire/ -- UK RECOVERY investigators found REGEN-COV reduced risk of death by 20% in patients hospitalized with COVID-19 who had not mounted their own immune response (primary outcome... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 16, 2021 Category: Pharmaceuticals Source Type: clinical trials

CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
TÜBINGEN, Germany / BOSTON, USA– June 16, 2021 -- CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 16, 2021 Category: Pharmaceuticals Source Type: clinical trials

Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer ’s Disease
CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topline results from its Phase 2 TANGO study of gosuranemab (BIIB092), an investigational anti-tau antibody that was being evaluated as a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 16, 2021 Category: Pharmaceuticals Source Type: clinical trials

COVID-19 Vaccine AstraZeneca Effective Against Delta ( ‘Indian’) Variant
15 June 2021 -- New data from Public Health England (PHE) demonstrated COVID-19 Vaccine AstraZeneca offers high levels of protection against the Delta variant (B.1.617.2; formerly the‘Indian’ variant). Real world data from... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 15, 2021 Category: Pharmaceuticals Source Type: clinical trials

Axsome Therapeutics Announces Planned NDA Submission for AXS-14 for the Management of Fibromyalgia
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced its plan... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 15, 2021 Category: Pharmaceuticals Source Type: clinical trials

Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
At the Day 15 primary endpoint, zuranolone 50 mg showed a statistically significant and clinically meaningful reduction in depressive symptoms as measured by HAMD-17 (p=0.0141) compared to placebo Rapid onset of treatment effect was seen in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 15, 2021 Category: Pharmaceuticals Source Type: clinical trials

Update on AZD7442 STORM CHASER Trial in Post-Exposure Prevention of Symptomatic COVID-19
15 June 2021 -- AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 15, 2021 Category: Pharmaceuticals Source Type: clinical trials

Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
COVID-19 vaccine candidate efficacy in those 18 to
Source: Drugs.com - Clinical Trials - June 14, 2021 Category: Pharmaceuticals Source Type: clinical trials